An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Some women's cancers are fueled by hormones such as estrogen and progesterone. GDC-0927 is an investigational drugs designed to interfere with cancer growth by blocking the female sex hormones that make some cancers grow.
In this study, researchers want to find the highest dose of GDC-0927 that can be given safely in postmenopausal women with locally advanced or metastatic breast cancer that contains estrogen receptors and continues to grow despite conventional hormonal therapy. GDC-0927 is a tablet that is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have locally advanced or metastatic estrogen receptor-positive breast cancer that has continued to grow despite at least six months of hormonal therapy (such as tamoxifen, aromatase inhibitors, or fulvestrant).
- Patients must be postmenopausal.
- Patients may have received up to two prior regimens of chemotherapy for advanced or metastatic breast cancer and must recover from any serious side effects before entering the study.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for women age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Maura Dickler at 646-888-5456.